Graeme Martin
President & CEO @ Takeda Ventures
Palo Alto, United States
Graeme Martin is a Series A investor at Takeda Ventures in Palo Alto focused on Biotechnology and Health Care. Dr. Martin is President and CEO of Takeda Ventures, Inc, with day-to-day responsibility for operations. He brings more than 30 years R&D experience in large Pharma as well as Biotech, and was responsible for three IND submissions one of which led to the launch of Zomig® now marketed worldwide for the acute treatment of migraine. Dr Martinjoined TVI in 2003, and has been responsible for building a portfolio of strategic investments representing more than US$45MM under management. He received his Bachelor of Science degree in Pharmacology from the University of Bath, UK and his doctorate from University College, London, UK.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 9%
Last updated:
For AI agents: llms.txt
Industries Graeme Martin invests in
Stages Graeme Martin invests in
Countries Graeme Martin invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 9 (82%)
- Health Care 6 (55%)
- Medical 4 (36%)
- Biopharma 2 (18%)
- Therapeutics 2 (18%)
Stage
- Series A 3 (27%)
- Series C 2 (18%)
- Series D 2 (18%)
- Venture - Series Unknown 2 (18%)
- Series B 1 (9%)
Country
- United States 5 (45%)
- United Kingdom 2 (18%)
- Belgium 1 (9%)
- Denmark 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. | $3.3M / Venture - Series Unknown / Oct 23, 2015 | ||
| Presage has developed a means of assessing tumor response to drugs or RNA interference agents without the limitations inherent to systemic administration. The Presage clinical surrogate approach enables drug companies to halt development projects for compounds that show no efficacy in the native tumor microenvironment. In addition, the Presageapproach can identify drug targets using RNA interference without concern regarding localization or distribution of systemically administered RNAi agents. Presage technology can also be used to identify effective drug combinations in ways that more directly measure the efficacy of such combinations than otherwise possible. | Venture - Series Unknown / Aug 20, 2015 | ||
| Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs),which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators. | $80M / Series C / Dec 03, 2014 | ||
| Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, StabilisedReceptors), overcoming a major limiting factor to the development of new drugs targeting this group. | $21M / Series B / Jun 27, 2013 | ||
| ArmaGen is a developer of therapies designed to address neurological complications. The company's pipeline of innovative therapies penetrate the blood-brain barrier to treat neurological complications of many diseases, including lysosomal storage disorders (LSDs), Alzheimer's and Parkinson's, enabling patients suffering fromneurodegenerative disorders to get improved treatment. | $17M / Series A / Nov 29, 2012 | ||
| Redwood Bioscience is utilizing precision protein-chemical engineering to develop optimized and novel biotherapeutics. The Company's site-specific modification technology overcomes the significant challenges associated with conjugating biologics to synthetic molecules to create homogenous hybrid biotherapeuticsIt was founded in 2008 andheadquartered in Emeryville, California. | Jun 27, 2011 | ||
| Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs),which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators. | $18M / Series A / May 11, 2011 | ||
| Serenex is a medical drug discovery and development company that focuses on oncology. The company develops Hsp90 product platform that provides a collection of small molecule Hsp90 inhibitors for cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases, such as Alzheimer's. It also developsSNX-1012, a product for oral mucositis in solid tumor patients.Serenex is a U.S.-based company that was founded in 2000 and it was acquired in 2008 by Pfizer. | $26M / Series D / Jun 28, 2007 | ||
| Lectus Therapeutics Limited is a UK-based pharmaceutical company. Its mission is to build a development pipeline containing first-in-class ion channel therapeutics identified through the use of its proprietary proteomics technology for pain management and the treatment of urinary bladder disorders. | $10.2M / Series A / Feb 13, 2006 | ||
| Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases. | $25M / Series D / Jan 10, 2006 | ||
| See all 11 investments → | |||
Co-Investors
About Takeda Ventures
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Takeda Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Michael Martin
Head of Takeda Ventures, Inc.
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Graeme Martin invest in?
Graeme Martin invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series C stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Graeme Martin?
Public channels for Graeme Martin include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Graeme Martin last invest?
The most recent investment recorded for Graeme Martin closed in Oct 2015. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
